U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07801664) titled 'Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer' on Aug. 31.
Brief Summary: For this study, high risk prostate cancer patients with lower risk ARTERA scores will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes. Specifically, patients enrolled in this study will undergo one of several dose-escalated forms of radiotherapy which would include SBRT with or without a brachytherapy boost.
Study Start Date: Aug. 06
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Intervention:
DRUG: Androgen Deprivation Therapy (A...